EUVIMEDEUVIMED entdecken
FallberichtÜbersichtsarbeitOpen Access · CC BY 4.0

Interplay of Belatacept Immunosuppression and Maribavir Antiviral Activity in Recurrent CMV Viremia: Clinical Implications and Literature Review

Imran Gani iD, Ahmad Mirza, Usman Baig

Viruses · 2025

DOI: 10.3390/v17050595 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Viruses, 2025. Verfasst von Imran Gani und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nephrology, Hypertension and Transplant Medicine, Wellstar MCG Health, Augusta University, Augusta, GA 30912, USA. Hauptthemen laut MEDLINE: Abatacept, Antiviral Agents, Benzimidazoles, Cytomegalovirus Infections. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 17 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Belatacept is a recombinant fusion protein used in renal transplant recipients, particularly when side effects from standard immunosuppressants occur. It offers a superior renal safety profile and is associated with better long-term renal graft outcomes. However, belatacept has been linked to atypical presentations of cytomegalovirus (CMV) infections, characterized by a prolonged and unpredictable course of viremia. We report a case involving a middle-aged African American female who developed acute kidney injury while on tacrolimus and was subsequently switched to belatacept. During treatment with belatacept, she experienced persistent and erratic CMV viremia lasting 58 weeks. The viremia showed an incomplete response to first-line antiviral therapy with valganciclovir, and the use of the novel antiviral agent maribavir also failed to achieve long-lasting viremic clearance. The resolution of the viremia was ultimately achieved only after discontinuing belatacept while continuing maribavir therapy. This case and literature review underscores the need for clinicians to remain vigilant for atypical CMV infections in renal transplant recipients treated with belatacept. If the complete clearance of viremia cannot be achieved despite the use of different antiviral agents, consideration should be given to modifying immunosuppressive therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AbataceptAntiviral AgentsBenzimidazolesCytomegalovirus InfectionsImmunosuppressive AgentsRibonucleosidesViremiaFemaleHumansMiddle AgedCytomegalovirusImmunosuppression TherapyKidney TransplantationRecurrenceDichlororibofuranosylbenzimidazole

Stichwörter der Autor:innen

belataceptcytomegalovirusimmunosuppressionkidney transplantmaribavirrecurrent viremia

Substanzen

AbataceptAntiviral AgentsBenzimidazolesImmunosuppressive AgentsmaribavirRibonucleosidesDichlororibofuranosylbenzimidazole

Autor:innen und Institutionen

  • Department of Nephrology, Hypertension and Transplant Medicine, Wellstar MCG Health, Augusta University, Augusta, GA 30912, USA.
  • Transplant Surgery Division, Wellstar MCG Health, Augusta University, Augusta, GA 30912, USA.

ORCID-Profile: Imran Gani

Zitieren

APA

Gani, I., Mirza, A., & Baig, U. (2025). Interplay of Belatacept Immunosuppression and Maribavir Antiviral Activity in Recurrent CMV Viremia: Clinical Implications and Literature Review. Viruses. https://doi.org/10.3390/v17050595

Vancouver

Gani I, Mirza A, Baig U. Interplay of Belatacept Immunosuppression and Maribavir Antiviral Activity in Recurrent CMV Viremia: Clinical Implications and Literature Review. Viruses. 2025. doi:10.3390/v17050595

BibTeX
@article{Gani2025,
  author = {Gani, Imran and Mirza, Ahmad and Baig, Usman},
  title = {Interplay of Belatacept Immunosuppression and Maribavir Antiviral Activity in Recurrent CMV Viremia: Clinical Implications and Literature Review},
  journal = {Viruses},
  year = {2025},
  doi = {10.3390/v17050595}
}
Kostenlos starten →